INOD

Innodata

$28.12

-8.91%
Nov 20, 2026
Bobby Quantitative Model
Innodata Inc. is a data engineering company that provides AI data preparation, model training and annotation, and AI deployment and integration services, primarily through its Digital Data Solutions segment, which generates the bulk of revenue alongside smaller Synodex and Agility businesses serving healthcare and financial data markets. It occupies a niche but strategically important position in the AI supply chain as an outsourced data-annotation and model-development partner to hyperscalers and large enterprises, making it a leveraged pure-play on enterprise AI infrastructure spending rather than a platform owner. The investor narrative has swung violently over the past year: a 149% rally in May 2026 on a large Q1 earnings beat, a lucrative new AI data contract, and raised guidance gave way to a punishing de-rating as a program loss, customer-concentration fears, and margin risk resurfaced, with shares down roughly 43% year-over-year and nearly 66% over six months. Bulls point to 52.9% year-over-year revenue growth, customer diversification progress, and an asymmetric small-cap AI opportunity, while bears focus on lumpy contract-driven revenue, a single-analyst coverage footprint, and a valuation that still embeds aggressive expectations despite the drawdown.

People also watch

IBM

IBM

IBM

Analysis
Accenture

Accenture

ACN

Analysis
Cognizant Technology Solutions

Cognizant Technology Solutions

CTSH

Analysis
Fiserv

Fiserv

FISV

Analysis
Broadridge Financial Solutions

Broadridge Financial Solutions

BR

Analysis

BobbyInvestment Opinion: Should I buy INOD Today?

Rating: Hold (speculative, risk-tolerant only). The core thesis is that Innodata's 52.87% YoY revenue growth and 16.48x forward PE on the lone analyst's $1.25 EPS estimate are attractive only if the Q3 gross-margin collapse to 37.17% proves to be temporary ramp cost rather than structural pricing pressure — and the evidence is not yet in. With no consensus price target available (single estimating analyst, EPS band of $1.19687-$1.29426) and the stock at its $32.59 52-week low, there is no analyst anchor to lean on, so the company's own contract disclosures and margin trajectory must carry the weight.

Supporting evidence is genuinely two-sided. On the positive side: revenue rose sequentially every quarter of 2026 ($90.10M → $92.14M → $95.62M) and grew 52.87% YoY; the balance sheet is pristine with debt-to-equity of 0.041, a current ratio of 2.68, and $163.97M of cash; ROE is 30.06% and TTM free cash flow is $117.67M; and PS has compressed to 6.44x from 39.24x a year ago, below even the 9.31x Q3 2024 trough. Against that: gross margin fell ~890 bps sequentially to 37.17%, operating margin fell to 9.05% from 17.21%, Q3 free cash flow flipped to -$86.36M from +$159.13M, and PB of 15.14x, EV/EBITDA of 31.93x, and PCF of 34.66x remain far above IT-services norms of 2-4x sales and 10-15x EBITDA. The unchanged 'Top Pick' (BWS, Sept 18) and 'Outperform' (Wedbush, June 5) ratings look stale against a 65.59% six-month decline.

The thesis would upgrade to Buy if Q4 gross margin recovers above 40% and free cash flow returns positive, confirming the margin hit was program-ramp cost, or if the stock reclaims the $44.74 October gap level on volume. It would downgrade to Sell if gross margin stays below 37% for a second quarter, if another major DDS program is lost, or if the analyst cuts the $1.25 EPS estimate — which would instantly make the 16.48x forward PE an illusion. On balance the stock is fairly-to-attractively valued on sales (6.44x PS at a multi-year trough) but expensive on book, EBITDA, and cash flow, and the earnings-based cheapness is entirely contingent on an unproven ramp; that asymmetry justifies patience rather than accumulation at the low.

Sign up to view all

INOD 12-Month Price Forecast

The forward view is genuinely balanced: the top line is compounding at 52.87% and the balance sheet ($163.97M cash, 0.041 debt-to-equity) removes solvency risk, but the Q3 margin collapse and the -$86.36M free-cash-flow swing show the earnings ramp underpinning the 16.48x forward PE is not yet proven. With only one estimating analyst and no consensus target, price discovery is inefficient and the unchanged 'Top Pick'/'Outperform' ratings look anchored to stale estimates rather than the October program loss. The stock at $32.59 sits at its 52-week low with no technical base, so the risk/reward is asymmetric only for investors who can tolerate another 30-40% drawdown. I would upgrade to bullish on a Q4 gross margin above 40% plus positive free cash flow, and downgrade to bearish on a second program loss or any cut to the $1.25 EPS estimate.

Historical Price
Current Price $28.12
Average Target $28.12
High Target $32.34
Low Target $23.90

Wall Street consensus

Coverage is extremely thin: only one analyst provides estimates, with an average EPS estimate of $1.2503 (range $1.19687-$1.29426) and average revenue estimate of $301.5 million (range $291.6 million-$309.7 million). No consensus recommendation or average price target is available in the provided data, so implied upside cannot be calculated; however, the institutional ratings history shows persistent bullishness from two firms — BWS Financial reiterated "Top Pick" as recently as September 18, 2026, and Wedbush reiterated "Outperform" on June 5, 2026 — with no downgrades recorded despite the 65% six-month collapse. That divergence between unchanged bullish ratings and a collapsing stock price is a red flag: either the analysts are anchored to stale estimates or the market is pricing in risks the sell-side has not yet incorporated.

With a single analyst, the target range is effectively the EPS estimate spread of $1.19687-$1.29426, an unusually tight ~8% band that reflects model precision rather than genuine conviction across a broad analyst community. The high end assumes the AI data-services ramp continues, new customer wins offset the program loss, and margins stabilize near Q2 levels; the low end likely assumes continued margin compression and slower contract ramps. The absence of broad coverage — typical of a small-cap with a $1.42-$1.62 billion market cap and limited institutional ownership — implies higher volatility, less efficient price discovery, and greater susceptibility to headline-driven gaps like the 25% single-day drop on October 27. Investors should treat the lone analyst's estimates as a directional signal, not a consensus anchor, and weight the company's own guidance and contract disclosures more heavily.

Drowning in data?

Find the real signal!

Bulls vs Bears: INOD Investment Factors

The bear case currently carries stronger near-term evidence: gross margin fell 890 bps sequentially, free cash flow flipped from +$159 million to -$86 million, a program loss triggered a 25% single-day gap, and the stock is pinned at its 52-week low with no technical floor. The bull case rests on the durability of 52.9% revenue growth and the 16.48x forward PE, which is only cheap if the analyst's $1.25 EPS estimate survives the margin compression now visible in the Q3 numbers. The single most important tension is whether the Q3 gross-margin decline to 37.17% is a temporary ramp cost on new programs or the start of structural pricing pressure in AI data services — if it is the former, the forward multiple is a bargain; if the latter, the earnings ramp that justifies 16.5x simply does not exist. Secondary but critical is customer concentration: the DDS segment is effectively the whole company, so one more program loss could break the growth narrative entirely. Until there is evidence of margin stabilization and a technical base above $44.74, the risk/reward skews toward the bear side despite the deeply compressed PS multiple.

Bullish

  • Revenue still compounding at 52.9% YoY: Q3 2026 revenue of $95.62 million grew 52.87% year-over-year and rose sequentially from $90.10 million in Q1 and $92.14 million in Q2, showing absolute expansion every quarter. Even after the program-loss headline, the core AI data-services engine is still delivering hyper-growth far above typical IT-services rates of mid-single to low-double digits.
  • Forward PE of 16.5x implies deep de-rating: The trailing PE of 50.45x collapses to a forward PE of 16.48x based on the single analyst's $1.25 average EPS estimate, implying earnings roughly triple from the current $0.0199 TTM EPS run-rate. If even a portion of that ramp materializes, the stock is priced like a value name rather than an AI growth asset at $32.59.
  • Pristine balance sheet with $164M cash: Debt-to-equity is just 0.041 and the current ratio is 2.68, with $163.97 million of cash at Q3-end against a ~$1.42-1.62 billion market cap. That liquidity buffer means the company can absorb a program loss and fund working-capital swings without dilutive financing, materially lowering solvency risk versus levered small-cap peers.
  • PS at multi-year trough of 6.44x: Price-to-sales has compressed from 39.24x in Q3 2025 to 6.44x now, below even the 9.31x Q3 2024 trough, while revenue has more than doubled over that span. The market has aggressively de-rated the multiple even as the top line expanded, creating a potential mismatch if growth proves durable.

Bearish

  • Gross margin collapsed 890 bps sequentially: Gross margin fell to 37.17% in Q3 2026 from 46.08% in Q2 and 43.40% in Q1, while operating margin dropped to 9.05% from 17.21% and 17.99% over the same quarters. SG&A rose to $26.88 million even as gross profit fell to $35.54 million, showing cost deleverage that directly undermines the earnings-triple thesis behind the 16.5x forward PE.
  • Free cash flow swung to -$86.4M: Q3 2026 operating cash flow was -$83.96 million and free cash flow -$86.36 million, driven by a -$102.86 million working-capital swing including a -$50.57 million accounts-payable drawdown, versus +$159.13 million FCF in Q2. That quarter-to-quarter whipsaw from +$159 million to -$86 million signals fragile cash conversion and raises questions about the quality of the TTM $117.67 million FCF.
  • Single-customer concentration and program loss: The DDS segment generated essentially all of the $95.62 million quarterly revenue, and the October 27 program-loss disclosure triggered a 25% single-day gap from $59.91 to $44.74. With revenue hinging on a handful of hyperscaler contracts, the loss of one program can move the stock double digits in a session, as it demonstrably did.
  • Falling knife at 52-week low: At $32.59 the stock sits at roughly 26.8% of its 52-week range and is down 65.59% over six months, 47.11% over three months, and 38.30% in the past month, with a -73.18% max drawdown from the $121.50 June peak. There is no technical base, and the sequence of lower highs ($43.81, $41.32, $38.62, $35.05, $32.59) confirms persistent distribution rather than capitulation.

INOD Technical Analysis

The prevailing trend is a severe, sustained downtrend: INOD is down 43.03% over one year, 47.11% over three months, and 65.59% over six months, with a maximum drawdown of -73.18% from its peak. At a current price of $32.59, the stock sits at roughly 26.8% of its 52-week range (low near $32.59, high near $121.50), meaning it is trading essentially at its lows rather than in mid-range consolidation. This positioning signals a falling knife rather than a value opportunity, with no evidence yet of a durable base, and the stock has lost more than half its value from the $121.50 June peak. Relative strength confirms the damage: -53.15% versus SPY over one year and -65.41% over six months, indicating the decline is company-specific rather than market-driven.

Short-term momentum is accelerating to the downside and diverging sharply from an already negative longer-term trend. The stock fell 38.30% in the past month and 47.11% in three months, with the most recent session down 8.09% on the day, and the 1-month relative strength of -35.25% versus SPY shows the selloff is intensifying rather than stabilizing. The October 27 gap from roughly $59.91 to $44.74 (-25% in a single session) marked a decisive breakdown, and the subsequent sequence of lower highs and lower lows through November ($43.81, $41.32, $38.62, $35.05, $32.59) confirms persistent distribution. With no RSI provided, the price action alone suggests deeply oversold conditions, but oversold readings in a structural downtrend have repeatedly failed to produce sustained bounces here.

Key technical levels are now defined by the recent price structure: immediate support sits at the current 52-week low of $32.59, and a breakdown below that level would open the door to further capitulation with no visible floor. Resistance is layered at the October gap zone around $44.74 and the prior consolidation shelf near $52.82-$56.57, with the 52-week high of $121.50 now a distant 273% above the current price. A reclaim of $44.74 would be the first sign of stabilization, while a close above $56.57 would be needed to suggest a trend reversal. Beta is not available in the provided data, but the -73.18% max drawdown and 25% single-day gap demonstrate extreme volatility that demands small position sizing and strict risk controls.

Beta

—

—

Max Drawdown

-76.9%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

-46.2%

Cumulative gain past year

PeriodINOD ReturnS&P 500
1m-53.6%-9.7%
3m-56.2%-9.9%
6m-70.5%-7.5%
1y-46.2%+4.7%
ytd-46.9%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

INOD Fundamental Analysis

Revenue is growing rapidly but decelerating at the margin: Q3 2026 revenue of $95.62 million rose 52.87% year-over-year, following $92.14 million in Q2 (+57.8% YoY versus $58.39 million) and $90.10 million in Q1 (+54.4% YoY versus $58.34 million), with Q4 2025 at $72.38 million (+22.3% YoY). The sequential progression from $72.38 million to $90.10 million to $92.14 million to $95.62 million shows continued absolute expansion, but the sequential growth rate has slowed to roughly 3.8% in Q3 from 24.5% in Q1, and the year-over-year growth rate has slipped from ~58% to ~53%. The DDS segment drives essentially all revenue ($95.62 million of the reported total), so the investment case hinges entirely on AI data-services demand and the durability of large customer contracts, which is precisely where the recent program-loss headline creates risk.

Profitability remains solid but is compressing: Q3 2026 net income was $10.33 million (10.8% net margin) on $35.54 million of gross profit, a 37.17% gross margin, down from 46.08% in Q2 and 43.40% in Q1. Operating income fell to $8.66 million (9.05% operating margin) from $15.86 million (17.21%) in Q2 and $16.21 million (17.99%) in Q1, while SG&A rose to $26.88 million from $26.60 million and $22.89 million, respectively. The margin trajectory is clearly negative — gross margin down ~890 basis points sequentially and operating margin down ~820 basis points — consistent with the "margin risks resurface" narrative and suggesting either pricing pressure, unfavorable revenue mix, or ramp costs on new programs. Trailing net margin of 12.79% and operating margin of 15.98% still compare favorably to typical IT-services economics, but the direction of travel is the key concern.

The balance sheet is a genuine strength: debt-to-equity is just 0.041, the current ratio is 2.68, and cash stood at $163.97 million at Q3-end, providing ample liquidity to fund operations without external financing. However, cash flow quality has deteriorated sharply: Q3 2026 operating cash flow was -$83.96 million and free cash flow -$86.36 million, driven by a -$102.86 million working-capital swing (including a -$50.57 million accounts-payable drawdown), a stark reversal from Q2's +$164.44 million operating cash flow and +$159.13 million FCF. The TTM free cash flow of $117.67 million and ROE of 30.06% look strong, but the quarterly volatility — from +$159 million to -$86 million in one quarter — signals working-capital timing risk and raises questions about the sustainability of the cash generation that underpins the bull case.

Quarterly Revenue

$95618000.0B

2026-09

Revenue YoY Growth

+52.9%

YoY Comparison

Gross Margin

37.2%

Latest Quarter

Free Cash Flow

$117671000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Operating Segments

Open an Account, get $2 TSLA now!

Valuation Analysis: Is INOD Overvalued?

Because net income is positive ($10.33 million in Q3, TTM EPS of $0.0199 per the key metrics), the PE ratio is the appropriate primary metric. The trailing PE is 50.45x versus a forward PE of 16.48x, an enormous 67% compression that implies the market expects earnings to roughly triple — consistent with the single analyst's $1.25 average EPS estimate versus the current run-rate. That gap is the entire valuation debate: if forward estimates are met, the stock is cheap at 16.5x; if the program loss and margin compression derail the earnings ramp, the trailing 50x multiple is unsupported. The PEG ratio of 16.48 and EV/EBITDA of 31.93x underscore how much growth is already embedded.

On peer comparison, INOD trades at a steep premium to typical IT-services multiples: PS of 6.44x, PB of 15.14x, and EV/EBITDA of 31.93x versus an industry where services firms often trade at 2-4x sales and 10-15x EBITDA. The premium is partially justified by 52.9% revenue growth and a 30.06% ROE, both far above sector norms, but the 15.14x price-to-book and 34.66x price-to-cash-flow leave little room for error. The market is valuing INOD as an AI-infrastructure growth asset rather than a services company, which is defensible only while growth and margins hold; the Q3 margin compression directly challenges that framing.

Historically, INOD's valuation has been extraordinarily wide-ranging: PE was 74.1x in Q3 2025, 54.8x in Q3 2026, and as low as 6.99x in Q3 2024, while PS ranged from 9.31x (Q3 2024) to 39.24x (Q3 2025) and now sits at 6.44x. The current PS of 6.44x is near the bottom of its multi-year band and below the 2024 trough, suggesting the market has aggressively de-rated the stock — either a value opportunity if fundamentals hold or a signal of fundamental deterioration. The current PE of 50.45x remains above the 2024-2025 average despite the 65% six-month decline, meaning the de-rating has been driven by falling earnings expectations as much as multiple compression.

PE

50.4x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 7x~74x

vs. Industry Avg

19.1x

Industry PE ~19.1x*

EV/EBITDA

31.9x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the sharp deterioration in profitability and cash conversion. Gross margin fell from 46.08% in Q2 2026 to 37.17% in Q3, a roughly 890 bps sequential decline, while operating income dropped from $15.86 million to $8.66 million and operating margin from 17.21% to 9.05%, even as SG&A edged up to $26.88 million. Free cash flow swung from +$159.13 million in Q2 to -$86.36 million in Q3 on a -$102.86 million working-capital swing, including a -$50.57 million accounts-payable drawdown, showing that reported TTM FCF of $117.67 million masks severe quarterly volatility. Revenue is also dangerously concentrated: the DDS segment accounts for essentially all of the $95.62 million quarterly top line, so the loss of a single hyperscaler program can gut both growth and margins simultaneously, as the October 27 disclosure demonstrated. The balance sheet is the offset — debt-to-equity of 0.041, current ratio of 2.68, and $163.97 million of cash — but liquidity does not fix a broken margin structure. Market and competitive risks are dominated by valuation compression and coverage fragility. At PB of 15.14x, EV/EBITDA of 31.93x, and price-to-cash-flow of 34.66x, INOD trades at a steep premium to IT-services norms of 2-4x sales and 10-15x EBITDA, leaving little cushion if growth decelerates from 52.9% toward the 22.3% seen in Q4 2025. Coverage is effectively one estimating analyst with an ~8% EPS band ($1.19687-$1.29426), so price discovery is inefficient and headline-driven gaps are amplified — the stock fell 25% in a single session on October 27 and 8.09% on the most recent day. Relative strength of -65.41% versus SPY over six months confirms the damage is company-specific rather than macro, but that also means any sector rotation away from small-cap AI names would compound the decline. Recent Zacks coverage explicitly flags 'program loss and margin risks resurfacing,' while Motley Fool frames the name as a speculative asymmetric bet, a split narrative that keeps volatility elevated. The worst-case scenario is a second major program loss combined with gross margin failing to recover above 40%, which would invalidate the $1.25 forward EPS estimate and force the trailing 50.45x PE to compress toward services-peer levels. In that chain, the stock breaks the current 52-week low of $32.59 with no visible technical floor, and a retest of the -73.18% max drawdown implies a price near $32.50 from the $121.50 peak — but from today's $32.59, a further 30-40% decline to the $20-23 range is plausible if estimates are cut. Realistically, an investor could lose another 30% to 40% from current levels in the adverse case, and the 25% single-day gap already demonstrates how quickly that damage can occur.

FAQ

The most severe risk is customer concentration: the DDS segment generated essentially all of the $95.62 million quarterly revenue, and the October 27 program-loss disclosure triggered a 25% single-day gap from $59.91 to $44.74, demonstrating how fast one contract can move the stock. Second is margin and cash-flow deterioration: gross margin fell to 37.17% from 46.08% sequentially, operating margin dropped to 9.05% from 17.21%, and free cash flow swung from +$159.13 million in Q2 to -$86.36 million in Q3 on a -$50.57 million accounts-payable drawdown. Third is valuation compression risk: PB of 15.14x, EV/EBITDA of 31.93x, and PCF of 34.66x leave little cushion if growth decelerates from 52.87% toward the 22.3% seen in Q4 2025, and the 16.48x forward PE depends entirely on a single analyst's estimate. Fourth is coverage and liquidity fragility: one estimating analyst with an ~8% EPS band ($1.19687-$1.29426) means inefficient price discovery, headline-driven gaps, and a -65.41% six-month relative strength versus SPY that confirms company-specific damage rather than macro-driven weakness.

The 12-month outlook splits into three scenarios with a 55% base case, 25% bear case, and 20% bull case. The base case targets $38-$50, assuming revenue growth decelerates toward the high-30s as the lost program annualizes, gross margin stabilizes in the 37-40% band, free cash flow returns positive, and the lone analyst holds the $1.2503 EPS estimate — leaving valuation near 7-8x PS. The bear case targets $20-$32, driven by a second program loss or gross margin staying below 37%, which would force an EPS estimate cut and break the $32.59 low with no technical floor. The bull case targets $65-$80, requiring Q4 gross margin above 40%, a new hyperscaler AI data contract, and renewed small-cap AI sector rotation lifting PS back toward 9-10x. The base case is most likely because the balance sheet ($163.97 million cash, 0.041 debt-to-equity) removes solvency risk and the top line is still compounding at 52.87%, but the key assumption — margin stabilization without a second program loss — is unproven and hinges on the Q4 report.

The answer depends entirely on which multiple you trust, and the dispersion is extreme. On sales, INOD looks undervalued: PS of 6.44x is below the 9.31x Q3 2024 trough and far below the 39.24x Q3 2025 peak, despite revenue more than doubling over that span. On earnings, the trailing PE of 50.45x collapses to a forward PE of 16.48x — but only if the lone analyst's $1.2503 EPS estimate is met, implying earnings roughly triple from the current $0.0199 TTM EPS run-rate. On book, EBITDA, and cash flow, the stock remains expensive: PB of 15.14x, EV/EBITDA of 31.93x, and price-to-cash-flow of 34.66x all sit far above IT-services norms of 2-4x sales and 10-15x EBITDA. The market is therefore pricing INOD as an AI-infrastructure growth asset rather than a services company, and the Q3 margin compression directly challenges that framing. Net verdict: fairly-to-attractively valued on sales at a multi-year trough, but expensive on book, EBITDA, and cash flow, with the earnings-based cheapness contingent on an unproven margin recovery.

From a pure risk/reward standpoint, INOD is a conditional buy at best and only for speculative, risk-tolerant investors. The upside case is anchored on 52.87% year-over-year revenue growth, a forward PE of 16.48x against the single analyst's $1.2503 EPS estimate, and a PS of 6.44x that sits below even the 9.31x Q3 2024 trough — implying the market has already priced in substantial deterioration. The downside is equally concrete: gross margin fell roughly 890 bps sequentially to 37.17%, free cash flow flipped to -$86.36 million, and the stock is at its $32.59 52-week low with no technical floor and a -73.18% max drawdown from the June peak. With only one estimating analyst and no consensus price target, there is no sell-side anchor to lean on, and the unchanged 'Top Pick' and 'Outperform' ratings look stale against a 65.59% six-month decline. It is a good buy only if Q4 gross margin recovers above 40% and free cash flow turns positive, confirming the margin hit was ramp cost rather than structural pricing pressure; otherwise the earnings-based cheapness is an illusion.

INOD is unsuitable for short-term trading unless the trader is comfortable with extreme volatility: the stock fell 25% in a single session on October 27, dropped 8.09% on the most recent day, and has a -73.18% max drawdown from its June peak, with a -38.30% one-month and -65.59% six-month decline. For long-term investors, the case is more defensible but still speculative: revenue is compounding at 52.87% in a structurally growing AI data-services market, the balance sheet is debt-free in substance, and ROE is 30.06%, but the company pays no dividend (0% yield, 0% payout ratio) and earnings visibility is poor given single-analyst coverage and lumpy hyperscaler contracts. A concrete minimum holding period of 18-24 months is appropriate, long enough to see whether the Q3 margin compression was ramp cost and whether customer diversification offsets the program loss. Position sizing should reflect the binary nature of the Q4 margin outcome — this is a satellite, not a core, holding.